Literature DB >> 18779884

Societal cost of skin cancer in Sweden in 2005.

Gustav Tinghög1, Per Carlsson, Ingrid Synnerstad, Inger Rosdahl.   

Abstract

Skin cancer is one of the most rapidly increasing cancers among the Swedish population and a significant cause of illness and death. This study aims to estimate the total societal cost of skin cancer in Sweden for 2005, using a prevalence-based cost-of-illness approach. The total cost of skin cancer was estimated at euro 142.4 million (euro 15/inhabitant), of which euro 79.6 million (euro 8/inhabitant) was spent on health services and euro 62.8 million (euro 7/inhabitant) was due to loss of production. The main cost driver was resource utilization in outpatient care, amounting to 42.2% of the total cost. Melanoma was the most costly skin cancer diagnosis. Non-melanoma skin cancer was, however, the main cost driver for health services alone. For the future it is important to establish effective preventive measures to avoid increasing costs and suffering caused by skin cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18779884     DOI: 10.2340/00015555-0523

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  18 in total

1.  Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden.

Authors:  E Heintz; A-B Wiréhn; B Bourghardt Peebo; U Rosenqvist; L-A Levin
Journal:  Diabetologia       Date:  2010-07-02       Impact factor: 10.122

2.  Nutritional status and health care costs for the elderly living in municipal residential homes--an intervention study.

Authors:  B Lorefält; A Andersson; A B Wirehn; S Wilhelmsson
Journal:  J Nutr Health Aging       Date:  2011-02       Impact factor: 4.075

3.  Squamous cell carcinoma of the skin: Emerging need for novel biomarkers.

Authors:  Atte Kivisaari; Veli-Matti Kähäri
Journal:  World J Clin Oncol       Date:  2013-11-10

4.  Social welfare and legal constraints associated with work among breast and prostate cancer survivors: experiences from Ireland.

Authors:  Linda Sharp; Aileen Timmons
Journal:  J Cancer Surviv       Date:  2011-06-17       Impact factor: 4.442

5.  A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.

Authors:  Keith Tolley; Danny Kemmett; Signe Thybo; Ruth Nasr; Helen Smethurst
Journal:  Eur J Health Econ       Date:  2015-03-21

Review 6.  Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature.

Authors:  Gery P Guy; Donatus U Ekwueme
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

7.  Ability to Predict Melanoma Within 5 Years Using Registry Data and a Convolutional Neural Network: A Proof of Concept Study.

Authors:  Martin Gillstedt; Sam Polesie
Journal:  Acta Derm Venereol       Date:  2022-07-13       Impact factor: 3.875

Review 8.  Melanoma treatment costs: a systematic review of the literature, 1990-2011.

Authors:  Gery P Guy; Donatus U Ekwueme; Florence K Tangka; Lisa C Richardson
Journal:  Am J Prev Med       Date:  2012-11       Impact factor: 5.043

9.  How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis.

Authors:  John Carstensen; David Andersson; Malin André; Sven Engström; Henrik Magnusson; Lars Axel Borgquist
Journal:  BMJ Open       Date:  2012-04-25       Impact factor: 2.692

10.  The cost of unresectable stage III or stage IV melanoma in Italy.

Authors:  Michele Maio; Paolo Ascierto; Alessandro Testori; Ruggero Ridolfi; Emilio Bajetta; Paola Queirolo; Michele Guida; Antonella Romanini; Vanna Chiarion-Sileni; Jacopo Pigozzo; Anna Maria Di Giacomo; Mario Calandriello; Guido Didoni; Marck van Baardewijk; Cyril Konto; Carlo Lucioni
Journal:  J Exp Clin Cancer Res       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.